State-owned pharmaceutical company PT Bio Farma is targeting to get emergency-use authorization for the domestically produced Indonesia Vaccine or Indovac from the Food and Drug Supervisory Agency (BPOM) in September 2022.
“We are almost done and in the process of registering at BPOM. For the results, Alhamdulillah (Thank God), the data collected during the clinical trials showed promising results,” president director of Bio Farma, Honesti Basyir, said here on Monday.
In terms of halal assessment, the Indovac vaccine has been audited by the Assessment Institute for Food, Drugs, and Cosmetics of the Indonesian Ulema Council (LPPOM MUI), so the vaccine will have halal certification soon, he informed.
The dosage and procedure for administering the Indovac vaccine are the same as for other COVID-19 vaccines circulating in Indonesia, which is two doses for the primary series, and one booster shot.
“We have put effort to set the price below Rp100 thousand because the manufacturing process is mostly being carried out in Indonesia,” Basyir said.
The pandemic has made all parties realize how fragile Indonesia’s health resilience is, he highlighted.
The State-Owned Enterprises (SOEs) Ministry had asked Bio Farma to make innovations so that Indonesia can be better prepared to face the pandemic and no longer needs to depend on vaccine imports.
Based on the directive, Bio Farma developed a COVID-19 vaccine, which was previously known as the BUMN or SOE Vaccine.
“A month ago, this vaccine was named Indonesia Vaccine or Indovac by the President,” Basyir said.
The vaccine is based on recombinant sub-unit proteins and has been developed in collaboration with Baylor College of Medicine (BCM).
Earlier, PT Bio Farma had said that it had completed a series of clinical trials for the vaccine so that Indonesia can get its own COVID-19 vaccine brand. \
Source: Antara News